(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Quarter results today
(bmo 2024-05-03)
Expected move: +/- 4.13%
0.36% INR 502.60
Live Chart Being Loaded With Signals
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...
Stats | |
---|---|
Volumen de hoy | 97 764.00 |
Volumen promedio | 210 437 |
Capitalización de mercado | 46.21B |
EPS | INR0 ( 2024-04-13 ) |
Próxima fecha de ganancias | ( INR0 ) 2024-07-18 |
Last Dividend | INR1.000 ( 2023-02-08 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 25.67 |
ATR14 | INR1.356 (0.27%) |
Volumen Correlación
Aarti Drugs Limited Correlación
10 Correlaciones Más Positivas | |
---|---|
BBL.NS | 0.955 |
RBLBANK.NS | 0.954 |
AIRAN.NS | 0.949 |
PGHH.NS | 0.944 |
KELLTONTEC.NS | 0.94 |
HPL.NS | 0.94 |
PREMEXPLN.NS | 0.939 |
SJVN.NS | 0.938 |
TWL.NS | 0.936 |
POLYCAB.NS | 0.934 |
10 Correlaciones Más Negativas | |
---|---|
LTGILTBEES.NS | -0.947 |
SINTEX.NS | -0.924 |
RAJRILTD.NS | -0.922 |
BOHRAIND.NS | -0.92 |
RAJVIR.NS | -0.911 |
BGLOBAL.NS | -0.906 |
IRISDOREME.NS | -0.906 |
OMAXE.NS | -0.905 |
JPINFRATEC.NS | -0.903 |
SRPL.NS | -0.901 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aarti Drugs Limited Correlación - Moneda/Commodity
Aarti Drugs Limited Finanzas
Annual | 2022 |
Ingresos: | INR27.16B |
Beneficio Bruto: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Ingresos: | INR27.16B |
Beneficio Bruto: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Ingresos: | INR24.89B |
Beneficio Bruto: | INR5.04B (20.24 %) |
EPS: | INR22.12 |
FY | 2021 |
Ingresos: | INR21.55B |
Beneficio Bruto: | INR6.00B (27.86 %) |
EPS: | INR30.09 |
Financial Reports:
No articles found.
Aarti Drugs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2003-11-13 |
Last Dividend | INR1.000 | 2023-02-08 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 32 | -- |
Total Paid Out | INR15.88 | -- |
Avg. Dividend % Per Year | 0.23% | -- |
Score | 2.13 | -- |
Div. Sustainability Score | 4.77 | |
Div.Growth Potential Score | 3.35 | |
Div. Directional Score | 4.06 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.250 | 0.18% |
2019 | INR0.250 | 0.17% |
2020 | INR3.00 | 2.03% |
2021 | INR0 | 0.00% |
2022 | INR1.000 | 0.18% |
2023 | INR1.000 | 0.22% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RVNL.NS | Dividend Knight | 2023-09-20 | Annually | 6 | 3.08% | |
LSIL.NS | Dividend Junior | 2023-07-17 | Annually | 3 | 0.23% | |
GEOJITFSL.NS | Dividend Knight | 2023-06-30 | Annually | 20 | 2.79% | |
ARVIND.NS | Dividend Junior | 2023-07-21 | Sporadic | 20 | 0.59% | |
THEMISMED.NS | Dividend Junior | 2023-08-31 | Sporadic | 18 | 0.39% | |
ORIENTELEC.NS | Dividend Junior | 2023-07-26 | Semi-Annually | 7 | 0.41% | |
IRFC.NS | Dividend Junior | 2023-09-15 | Annually | 4 | 2.61% | |
CUB.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 0.35% | |
SHRADHA.NS | Dividend Junior | 2023-07-06 | Sporadic | 6 | 0.99% | |
MAPMYINDIA.NS | Dividend Junior | 2023-08-25 | Annually | 3 | 0.13% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0680 | 1.500 | 8.64 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.150 | 1.500 | 9.44 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 8.41 | 1.000 | 8.00 | 8.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 4.52 | 9.04 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.322 | 1.000 | 7.96 | 7.96 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.105 | 1.000 | 9.91 | 9.91 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 25.47 | 1.000 | 7.53 | 0 | [1 - 100] |
returnOnEquityTTM | 0.150 | 2.50 | 9.64 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 9.04 | [0 - 30] |
dividendYielPercentageTTM | 0.200 | 1.500 | 4.99 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.349 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0380 | 1.000 | -1.550 | 0 | [0.1 - 0.5] |
Total Score | 3.35 |
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico